<DOC>
	<DOCNO>NCT00541021</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy gemcitabine , work different way stop growth tumor cell , either kill cell stop dividing . Sorafenib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . It yet know whether give gemcitabine together sorafenib effective give gemcitabine alone treat pancreatic cancer . PURPOSE : This randomized phase III trial study give gemcitabine together sorafenib see well work compare give gemcitabine alone treat patient locally advance metastatic pancreatic cancer .</brief_summary>
	<brief_title>Gemcitabine With Without Sorafenib Treating Patients With Locally Advanced Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare progression-free survival . Secondary - Compare toxicity . - Compare response rate . - Compare overall survival . - Evaluate clinical benefit . - Compare quality life . - Identify biomarkers predict therapeutic response . OUTLINE : This multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral sorafenib tosylate twice daily gemcitabine hydrochloride IV weekly 7 week follow 1 week rest ( course1 ) . For next 2 course , patient receive gemcitabine hydrochloride weekly 3 week follow 1 week rest sorafenib tosylate twice daily . - Arm II : Patients receive oral placebo twice daily gemcitabine hydrochloride arm I . After complete 3 course therapy , patient arm stable respond disease may continue receive sorafenib tosylate placebo absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Inclusion criterion : Diagnosis adenocarcinoma pancreas Locally advance metastatic disease Measurable disease , define least 1 lesion measurable RECIST criterion Exclusion criterion : Brain metastases PATIENT CHARACTERISTICS : Inclusion criterion : WHO performance status 02 Absolute neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Creatinine &lt; 1.5 time normal Transaminases &lt; 2 time normal ( 5 time normal liver metastasis ) Total bilirubin &lt; 1.5 time normal Fertile patient must use effective contraception Exclusion criterion : Pregnant nursing Intestinal occlusion Prior inflammatory intestinal disease Crohn 's disease Hemorrhagic rectal colitis Peripheral neuropathy &gt; grade 2 Other severe illness , include follow : Unstable cardiac disease , even treat Psychological neurological disease include dementia Uncontrolled active infection Other severe illness would compromise study participation Impossible receive study therapy due geographical , social , psychological reason Other malignancy within past 5 year except basal cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Inclusion criterion : See Disease Characteristics At least 6 month since prior chemotherapy radiochemotherapy At least 4 week since prior radiotherapy and/or surgery Exclusion criterion : Prior therapy advance disease Prior inhibitor kinase signal ( e.g. , ras/raf , MEK , AKT , mTOR , farnesyl transferase ) Prior inhibitor angiogenesis ( e.g. , bevacizumab ) Prior organ graft allogeneic transplantation Prior extensive intestinal resection Concurrent participation another therapeutic study Concurrent inductor CYP3A4 ( e.g. , barbiturate , antiepileptic , rifampicin )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
</DOC>